Success Metrics

Clinical Success Rate
86.1%

Based on 62 completed trials

Completion Rate
86%(62/72)
Active Trials
3(4%)
Results Posted
45%(28 trials)
Terminated
10(12%)

Phase Distribution

Ph phase_2
25
29%
Ph phase_3
21
25%
Ph phase_4
23
27%
Ph not_applicable
7
8%
Ph phase_1
4
5%

Phase Distribution

4

Early Stage

25

Mid Stage

44

Late Stage

Phase Distribution80 total trials
Phase 1Safety & dosage
4(5.0%)
Phase 2Efficacy & side effects
25(31.3%)
Phase 3Large-scale testing
21(26.3%)
Phase 4Post-market surveillance
23(28.7%)
N/ANon-phased studies
7(8.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.9%

62 of 73 finished

Non-Completion Rate

15.1%

11 ended early

Currently Active

3

trials recruiting

Total Trials

85

all time

Status Distribution
Active(5)
Completed(62)
Terminated(11)
Other(7)

Detailed Status

Completed62
Terminated10
unknown7
Active, not recruiting2
Recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
85
Active
3
Success Rate
86.1%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (5.0%)
Phase 225 (31.3%)
Phase 321 (26.3%)
Phase 423 (28.7%)
N/A7 (8.8%)

Trials by Status

recruiting11%
completed6273%
enrolling_by_invitation11%
not_yet_recruiting11%
withdrawn11%
terminated1012%
unknown78%
active_not_recruiting22%

Recent Activity

Clinical Trials (85)

Showing 20 of 85 trialsScroll for more
NCT06264609Phase 4

Precision Medicine Approach for Osteoporosis - Follow Up Study

Enrolling By Invitation
NCT07216794Phase 2

Small Trial of Alendronate Impact on the Reservoir of HIV

Not Yet Recruiting
NCT04708886Phase 2

Romosozumab in Women With Chronic SCI

Completed
NCT07028320Phase 3

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

Completed
NCT05151484Phase 4

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Recruiting
NCT01631214Phase 3

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Completed
NCT06772792Phase 1

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

Completed
NCT00480662Phase 3

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Completed
NCT00092014Phase 3

A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

Completed
NCT06264401Not Applicable

Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis

Completed
NCT03396315Phase 2

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

Completed
NCT02944799Phase 2

Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis

Completed
NCT01460654Phase 2

Testosterone and Alendronate in Hypogonadal Men

Terminated
NCT00580047Not Applicable

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

Completed
NCT03623633Phase 4

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Active Not Recruiting
NCT02195895Phase 2

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

Completed
NCT05662358Not Applicable

Denosumab vs Alendronate After Vertebroplasty

Unknown
NCT02440581Not Applicable

Renal Osteodystrophy: An Individual Management Approach

Completed
NCT05645289Phase 4

Efficacy and Safety of Minodronate in Patients With Low Back Pain

Unknown
NCT00896532Phase 2

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

Completed

Drug Details

Intervention Type
DRUG
Total Trials
85